San Francisco startup Structure Therapeutics can also be working on an oral, after-daily GLP-one drug identified as GSBR-1290—the drug surpassed Wall Road’s anticipations in June every time a mid-stage analyze confirmed common weight loss of all over 6% and it plans to start another